Prescription Drug Affordability Board Activity, December 2025
Activities Summary
Colorado: In October, Colorado's PDAB heard testimony about its decision to set an upper payment limit on Enbrel, and set price of $600 per 50mg/1ml, effective January 1, 2027. The board's next meeting is January 9, 2026.
Maryland:The PDAB met on December 8, 2025 to review a draft of its annual report to the legislature. The board's January meeting was cancelled due to inclement weather.
Oregon: The PDAB met on December 17, 2025 to approve its annual legislative report, and to discuss both the 2026 drug review process and consider drugs to inclusion in a March report to the Oregon Legislature. The next meeting is January 21, 2026.
Washington: Washington's PDAB met on November 19, 2025 to discuss the best ways to present data in 2026, and to hear public comment. They will next meet on March 18, 2026.
Activity by State
Maryland
Maryland PDAB Meeting, December 8, 2025
Public Comment
In December, Maryland’s PDAB received written public comments and heard oral public comments during the meeting from:
- Derek Flowers from the Value of Care Coalition,
- George Huntley from Diabetes Patient Advocacy Coalition, and
- Mary Morlino, a rare disease patient and founder of MarylandRare.
Chair Van Mitchell validated Derek Flowers' concern about the lack of progress of the board over the past five years. He cited short staffing for the lack of progress, and said the board was considering policy alternatives to UPLs.
Annual Report Approval
In their review of the annual report, the board concluded that they may support legislation related to prescription drug cost transparency, patient navigation services, and biosimilar interchangeability and competition. (A presentation about the Annual Report and a draft of the document may be found here.)
To end the meeting, Chair Mitchell announced Dr. Eberechukwu Onukwugha’s resignation.
The board's next meeting was scheduled forJanuary 26, 2026.
Oregon
Oregon PDAB Meeting, December 17, 2025
Public Comment
In December, Oregon’s PDAB received written public comments and heard oral public comments during the meeting from:
- Dharia McGrew, on behalf of PhRMA,
- Jessica McBride from the Oregon Coalition for Affordable Prescriptions, and
- Ranier Simons from Community Access National Network,
Discussion and vote on the annual report
After minor discussion about the wording of policy recommendations, the board approved the 2025 Annual Report to the Oregon Legislature.
2026 drug review
Staff members presented the 2024 data to be analyzed in 2026. The preliminary list included 650 products, which staff narrowed by filtering out drugs reported by fewer than five insurers. This was meant to ensure that the board would be assessing the cost of medicines with broad market presence. They arrived at 137 non-insulin products to consider.
2025 drug review
The board discussed which drugs among the 23 prescription medicines and insulin products they reviewed in 2025 to include in their March report to the Oregon legislature. They can include up to nine, including at least one insulin product. Each member came to the meeting with their own list of drugs they would nominate to send to the legislature. They will vote on the specific drugs in the January meeting.